1. Basic Information
Disease Protected Against
Seasonal influenza is a respiratory viral infection causing annual epidemics. Disease burden varies substantially by season, circulating strains, and population immunity. In the U.S., influenza causes an estimated 9–41 million illnesses, 140,000–710,000 hospitalizations, and 12,000–52,000 deaths annually (2010–2023 average). Children <5 years (especially <2) and children with underlying medical conditions are at highest risk for severe complications. The 2009 H1N1 pandemic was a reminder of pandemic influenza risk, though seasonal and pandemic vaccines are distinct products.
CDC Schedule (U.S., 2025)
| Population | Recommendation |
|---|---|
| All persons ≥6 months without contraindication | Annual influenza vaccination (universal recommendation since 2010) |
| Children 6 months–8 years (first-time vaccination) | 2 doses, ≥4 weeks apart (priming series) |
| Children 6 months–8 years (previously vaccinated) | 1 dose annually |
| Pregnant women | IIV recommended in any trimester; LAIV contraindicated |
Source: CDC ACIP. Multiple products available: egg-based IIV, cell-culture-based IIV (Flucelvax), recombinant HA vaccine (Flublok), and LAIV (FluMist, intranasal). For the 2024–25 season and beyond, all U.S. influenza vaccines are trivalent (H1N1, H3N2, and one B lineage, following the global disappearance of the Yamagata B lineage).
Notable Historical Safety Events
- 1976 Swine flu vaccine and GBS: The 1976 H1N1 swine flu vaccine was associated with an estimated ~1 excess case of Guillain-Barré Syndrome per 100,000 doses. This vaccine was withdrawn. The 1976 GBS association is the most significant safety event in influenza vaccine history and is the reference point against which all subsequent influenza vaccine GBS surveillance is compared.
- 2009 H1N1 pandemic vaccines (monovalent): Some European countries identified a small increased risk of narcolepsy following Pandemrix (AS03-adjuvanted H1N1 vaccine used in Europe; not used in the U.S.), estimated at ~3–7 excess cases per 100,000 vaccinated children. The mechanism is thought to involve molecular mimicry between the H1N1 nucleoprotein and the hypocretin receptor in genetically susceptible individuals (HLA-DQB1*0602). This adjuvant and formulation were not used in U.S. seasonal vaccines.
- 2014–2015 LAIV reduced effectiveness: LAIV (FluMist) showed low effectiveness against H1N1pdm09 during the 2013–14 and 2015–16 seasons. ACIP recommended against LAIV use in 2016–17 and 2017–18; LAIV was reformulated and re-recommended starting 2018–19.
2. Pre-Licensure Clinical Trial Data
Because influenza vaccines are reformulated annually, the typical pre-licensure paradigm does not apply in the same way as for other vaccines. New products undergo initial licensure with full clinical trials; subsequent annual strain changes are licensed based on manufacturing process consistency and immunogenicity data in smaller bridging studies (per FDA guidance).
| Product Type | Initial Licensure Database | Seasonal Strain Changes |
|---|---|---|
| Egg-based IIV | Licensure dating to 1940s (original products); modern products: ~3,000–5,000 per age group | Bridging immunogenicity studies; ~300–500 participants per strain update |
| LAIV (FluMist) | ~28,000 children across pivotal trials (originally licensed 2003) | Bridging studies; extensive post-licensure data |
| Cell-culture IIV (Flucelvax) | ~7,000 in pivotal trials (licensed 2012) | Bridging studies |
Most Common Adverse Reactions (Seasonal IIV)
| Reaction | IIV (children) | LAIV (children) |
|---|---|---|
| Injection site pain/tenderness | ~40–65% | N/A (intranasal) |
| Injection site redness/swelling | ~10–20% | N/A |
| Fever | ~5–15% (children <5) | ~5–10% |
| Runny nose/nasal congestion | ~10–20% | ~40–60% (expected; administered intranasally) |
| Headache | ~10–20% | ~15–25% |
| Fatigue/malaise | ~15–25% | ~10–20% |
| Wheezing (LAIV, children <2 with asthma history) | N/A | Increased risk; contraindicated in children <2 and those with asthma/wheezing |
Key Limitations
- Variable effectiveness: Influenza vaccine effectiveness ranges from ~10–60% depending on season, strain match, age, and prior vaccination. This is fundamentally different from other childhood vaccines with >85% effectiveness. The need for annual reformulation is a unique limitation.
- Prior vaccination effects: Repeated annual vaccination may reduce vaccine effectiveness in some seasons (antigenic distance hypothesis), though data are inconsistent. This is actively studied.
- Annual safety data limited: Strain-change bridging studies are small (hundreds of participants). Most safety evidence is post-licensure.
- Febrile seizure risk with PCV13 combination: In the 2010–11 season, co-administration of IIV and PCV13 was associated with an increased febrile seizure risk (~1 per 2,000 doses). This was season- and product-specific. (This is also noted on the PCV page.)
3. Post-Licensure Safety Data
VSD Findings
- Guillain-Barré Syndrome (GBS): The VSD and other surveillance systems have estimated the GBS risk following seasonal influenza vaccine at ~1–2 excess cases per million doses, substantially lower than the 1976 swine flu vaccine risk (~1 per 100,000). Some seasons show no statistically significant increase. IOM (2012) concluded evidence favors acceptance of a causal relationship for influenza vaccine and GBS (based primarily on the 1976 vaccine data; evidence for seasonal vaccines is less robust).
- Febrile seizures (IIV + PCV13, 2010–11): Signal identified and resolved. See PCV page.
- No increase in adverse pregnancy outcomes with IIV during pregnancy. Extensive VSD and registry data are consistent.
- Anaphylaxis: ~1–2 per million doses.
⚠ Critical Caveat
VAERS data represent unverified reports. A report to VAERS does not mean the vaccine caused the event. Because influenza vaccine is given annually to very large populations, VAERS report volumes are high relative to other vaccines, reflecting exposure volume rather than elevated risk.
4. Documented Adverse Events
▶ Strong Evidence
- Injection site reactions: 40–65% (pain). Strong
- Systemic reactions: Fever (5–15% in young children), fatigue, headache, myalgia. Strong
- Oculorespiratory syndrome (ORS): Transient red eyes, cough, wheezing within 24 hours of IIV. Reported primarily in Canada with one specific product in 2000–2001. Self-limited. Strong
- Anaphylaxis: ~1–2 per million doses. Strong
- Wheezing (LAIV in young children with asthma): Contraindication in children <2 and those with asthma. Strong
▶ Moderate Evidence
- GBS: ~1–2 excess cases per million doses with seasonal IIV (vs. ~1 per 100,000 with 1976 swine flu vaccine). Evidence is stronger for the 1976 vaccine specifically. Moderate
▶ No Causal Association
- Autism: No association. IOM (2012) rejected causality. No Association
- Narcolepsy (U.S. seasonal vaccines): The narcolepsy signal was specific to Pandemrix (AS03-adjuvanted, used in Europe). No signal with U.S. seasonal vaccines. No Association
5. Disease Prevention Benefits
| Metric | Pre-Vaccine / No Vaccination | With Vaccination |
|---|---|---|
| Pediatric influenza hospitalizations (U.S., annual) | ~20,000–60,000 (children <5) | VE against pediatric hospitalization: ~40–60% in most seasons; prevents thousands of hospitalizations annually |
| Pediatric influenza deaths (U.S., annual) | ~100–200 reported (underestimated) | ~50–80% of pediatric deaths occur in unvaccinated children; vaccination reduces ICU admission risk by ~74% |
| Maternal influenza vaccination | — | Reduces influenza in infants <6 months by ~50–70% (infants cannot be vaccinated before 6 months) |
Source: CDC MMWR, FluView; CDC Pink Book. Effectiveness varies by season. In the 2023–24 season, pediatric VE against hospitalization was ~52–61%, and >80% of influenza-associated pediatric deaths occurred in unvaccinated children.
6. Evidence Summary
Influenza vaccines differ fundamentally from other childhood vaccines in their variable effectiveness (10–60%), annual reformulation, and the resulting constant need for new post-licensure safety and effectiveness data each season. The safety profile for seasonal IIV is well-established after decades of use in hundreds of millions of annual doses. The primary historical safety concern — the 1976 GBS signal — has not been replicated at comparable magnitude with seasonal vaccines. The narcolepsy signal was adjuvant- and product-specific (Pandemrix). The main evidence limitation is the inherent inability to fully evaluate very rare adverse events for each new seasonal formulation, which is mitigated by the consistency of the manufacturing platform and the extensive passive and active surveillance infrastructure.
7. Key References
- IOM. Adverse Effects of Vaccines: Evidence and Causality. National Academies Press; 2012.
- CDC. Pink Book — Influenza chapter. cdc.gov/pinkbook
- Schonberger LB, et al. Guillain-Barré syndrome following vaccination in the National Influenza Immunization Program, United States, 1976–1977. Am J Epidemiol. 1979;110(2):105–123.
- Nohynek H, et al. AS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland. PLoS One. 2012;7(3):e33536.
- CDC. FluView — Weekly U.S. Influenza Surveillance Report. cdc.gov/flu/weekly
- CDC. VSD. cdc.gov/vaccine-safety/about/vsd.html
- CDC/FDA. VAERS. vaers.hhs.gov